TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07701941: A Phase 1b/2, Multicenter, Open-label, Dose Regimen Determination and Dose Expansion Trial to Evaluate the Safety, Tolerability, Anti-tumor Activity, and an Optimal Dose Regimen of Patritumab Deruxtecan (HER3-DXd) With T

Sponsor: Daiichi Sankyo · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 220 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$471,240

Rescue Site Savings

+$314,160

Unlock Full NCT07701941 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07701941 Rescue Dossier →